What’s Propelling Akari Therapeutics Plc – American Depositary Share (NASDAQ:AKTX) After Higher Shorts Reported?

April 17, 2018 - By Peter Erickson

Akari Therapeutics, Plc (NASDAQ:AKTX) Logo

The stock of Akari Therapeutics Plc – American Depositary Share (NASDAQ:AKTX) registered an increase of 0.94% in short interest. AKTX’s total short interest was 470,500 shares in April as published by FINRA. Its up 0.94% from 466,100 shares, reported previously. With 170,400 shares average volume, it will take short sellers 3 days to cover their AKTX’s short positions. The short interest to Akari Therapeutics Plc – American Depositary Share’s float is 8.23%.

The stock increased 5.64% or $0.1112 during the last trading session, reaching $2.0812. About 21,032 shares traded. Akari Therapeutics, Plc (NASDAQ:AKTX) has declined 72.00% since April 17, 2017 and is downtrending. It has underperformed by 83.55% the S&P500.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company has market cap of $31.75 million. The Company’s lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. It currently has negative earnings. The firm is based in New York, New York.

Akari Therapeutics, Plc (NASDAQ:AKTX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: